Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.
The Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. mRNA are equally as important.
Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.
Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans specific to the patient.
Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.
Testing for a specific cancer protein markers in lung cancer patients' blood helps find those more likely to respond to Tarceva, a drug sold by Roche.
CBSA's May BioBreakfast allowed two of Colorado's 2009 Bioscience success stories to share their stories. First up was Biodesix, in the diagnostic space.
Presenting current issues with lung cancer tissue testing, followed by a discussion of Veristrat, Biodesix proteomic serum test for predicted tumor response
A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively.
One data point doesn't tell you very much in most cases. This principle guides Biodesix's approach to developing diagnostics.